FY2025 EPS Estimates for Lonza Group Raised by William Blair

Key Points

• William Blair has raised its FY2025 earnings per share (EPS) estimates for Lonza Group to $2.07, up from the previous forecast of $2.03, with the consensus estimate for the current year being $1.88.
• Lonza Group has recently increased its dividend to $0.1054 per share, reflecting a 0.15% dividend yield, which is an increase from the previous $0.10.
• As of the latest trading session, Lonza Group's stock was down 1.8% and is currently trading around $71.16.

Lonza Group Ag (OTCMKTS:LZAGY - Free Report) - William Blair raised their FY2025 EPS estimates for Lonza Group in a report issued on Wednesday, July 23rd. William Blair analyst M. Smock now anticipates that the company will post earnings per share of $2.07 for the year, up from their prior forecast of $2.03. The consensus estimate for Lonza Group's current full-year earnings is $1.88 per share. William Blair also issued estimates for Lonza Group's FY2026 earnings at $2.45 EPS.

Lonza Group Trading Down 1.8%

Lonza Group stock opened at $71.16 on Friday. Lonza Group has a 12-month low of $55.57 and a 12-month high of $73.29. The company has a quick ratio of 1.04, a current ratio of 1.52 and a debt-to-equity ratio of 0.45. The firm's fifty day moving average price is $69.73 and its 200 day moving average price is $66.48.

Lonza Group Increases Dividend

The business also recently declared a dividend, which was paid on Friday, May 30th. Shareholders of record on Thursday, May 15th were given a dividend of $0.1054 per share. This represents a dividend yield of 0.15%. This is an increase from Lonza Group's previous dividend of $0.10. The ex-dividend date was Wednesday, May 14th.

Lonza Group Company Profile

Lonza Group AG, together with its subsidiaries, supplies various products and services for pharmaceutical, biotech, and nutrition markets in Europe, North and Central America, Latin America, Asia, Australia, New Zealand, and internationally. It operates through Biologics, Small Molecules, Cell & Gene, and Capsules & Health Ingredients segments.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.